ZYME Zymeworks Inc.

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Zii

Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.

Why Zymeworks Stock Is Back in Focus After FDA Approval Zymeworks (ZYME) moved into the spotlight after the FDA approved zanidatamab for first line HER2 positive gastroesophageal adenocarcinoma, putting fresh attention on what this decision might imply for future revenue potential. Against this backdrop, Zymeworks has seen momentum build, with a 30 day share price return of 28.31% and a 90 day gain of 15.44%. The 1 year total shareholder return of 95.49% and very large 3 year total...

Zymeworks stock has delivered very strong returns over the past three years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like a clear bargain. Recent gains and optimism around its HER2-targeting therapy are now being weighed against signals that point to limited valuation cushion at today’s levels. Zymeworks has returned about 301% over the past three years, which puts extra focus on whether recent gains already reflect much of the good...

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Jazz Pharmaceuticals plc’s two Ziihera-containing combination regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. Zanidatamab is being developed in multiple clinical trials as...

SJM raised its annual outlook following a quarterly earnings beat, while ZYME gained on price-target hikes tied to Ziihera’s FDA approval.

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA. Ziihera, or zanidatamab, is approved in combination with tisl

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.

Zymeworks (NASDAQ:ZYME) shares climbed nearly 4. 0% in pre-market trading as investors positioned themselves ahead of an important U.

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.

Zymeworks (ZYME) delivered earnings and revenue surprises of -10.71% and +25.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly sales. The company raised its full-year revenue outlook and said it is preparing for a potential A

Zymeworks Inc. (NASDAQ:ZYME) is one of the best small cap stocks to buy with the highest upside potential. Truist lifted the price target on Zymeworks Inc. (NASDAQ:ZYME) to $31 from $28 on July 7 and maintained a Buy rating on the shares. The rating update came as part of a broader research note, with the firm […]